Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2006
09/14/2006US20060204551 Synergistic salivation agents
09/14/2006US20060204550 Food and beverages containing L-carnitine derivatives
09/14/2006US20060204548 Microimplants for ocular administration
09/14/2006US20060204547 Drug delivery stent with extended in vivo release of anti-inflammatory
09/14/2006US20060204543 Semirigid implant of glycolic acid-lactic acid copolymer with hydroxypropylmethyl cellulose as release modifier for cyclosporine; biodegradation; sustained release
09/14/2006US20060204537 Silicone blends and composites for drug delivery
09/14/2006US20060204530 Benzoyl peroxide compositions and methods of use
09/14/2006US20060204526 Emulsive composition containing Dapsone
09/14/2006US20060204518 Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols
09/14/2006US20060204517 Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols
09/14/2006US20060204505 Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
09/14/2006US20060204504 Reducing leakage from unwanted choroidal neovasculature by administering an anti-FasL factor to permit an effective amount to localize in the neovasculature, administering a photosensitizer to the neovasculature, and irradiating it with laser light; photodynamic therapy
09/14/2006US20060204502 Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists
09/14/2006US20060204486 combination therapy of flibanserin with an antipsychotic drug
09/14/2006US20060204481 Methods of promoting cell viability
09/14/2006US20060204478 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
09/14/2006US20060204474 Treatment of epithelial layer lesions
09/14/2006US20060204472 Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery systems
09/14/2006US20060204471 Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging
09/14/2006US20060204466 Hydroalcoholic antimicrobial composition with skin health benefits
09/14/2006US20060204459 Use of tyrosine inhibitors for whitening human skin and treating melanocyted dysfunction associated diseases
09/14/2006US20060204450 Pharmaceutical Compositions Based On Anticholinergics and PDE 5-Inhibitors
09/14/2006US20060204449 Nasal pharmaceutical composition of piribedil
09/14/2006US20060204448 Powdery preparation for nasal administration
09/14/2006US20060204447 Delivering, via small particle aerosol, aqueous dispersions of anti-cancer drugs in liposomes or lipid complexes to respiratory tract of an individual in need of such treatment
09/14/2006US20060204446 Topical immunotherapy and compositions for use therein
09/14/2006US20060204444 Protein cages for the delivery of medical imaging and therapeutic agents
09/14/2006US20060204443 Methods for tumor treatment using dendrimer conjugates
09/14/2006US20060204441 Cell scaffold matrices with incorporated therapeutic agents
09/14/2006US20060204440 Radio-opaque polymeric biomaterials
09/14/2006US20060204437 Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
09/14/2006US20060201379 Applying paint, protective coating of Medetomidine which adsorbs strongly to metal nanoparticles; improves the performance of antifouling paints
09/14/2006US20060201212 End cover assembly for a hollow structural member
09/14/2006DE19922287B4 Verwendung von Flavonoidestern in Kosmetika Use of Flavonoidestern in cosmetics
09/14/2006DE102006006115A1 New quinoxaline derivatives useful e.g. in cosmetic and pharmaceutical preparation as photo stable UV-filter with reduced skin penetration potential to protect human skin or hair against sun radiation
09/14/2006DE102005011058A1 Substituierte Tetrahydro-pyrrolo-chinolinderivate Substituted tetrahydro-pyrrolo-quinoline derivatives
09/14/2006DE102005010770A1 Producing 1,4-diphenylazetidinone derivatives useful as cholesterol resorption inhibitors from protected beta-substituted amino amides comprises using a quaternary phosphonium salt catalyst
09/14/2006DE102005010255A1 Faserfreies transdermales therapeutisches System und Verfahren zu seiner Herstellung Fibre-free transdermal therapeutic system and process for its preparation
09/14/2006DE102005009194A1 Verfahren zur Herstellung von polymorph stabilem Triamcinolonacetonid A process for producing polymorphic stable triamcinolone acetonide
09/14/2006CA2745782A1 Pharmaceutical compositions and uses for peptide treatment
09/14/2006CA2640120A1 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo(3.1.0) hexanes
09/14/2006CA2604071A1 Antipruritic agent for pruritus caused by multiple sclerosis
09/14/2006CA2602010A1 Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin
09/14/2006CA2601980A1 1-acetic acid-indole derivatives with pgd2 antagonist activity
09/14/2006CA2601978A1 Quinoxaline dihydrohalide dihydrates and synthetic methods therefor
09/14/2006CA2601279A1 Formulation for aviptadil
09/14/2006CA2601028A1 Flavonoid compounds and uses thereof
09/14/2006CA2600886A1 Bicyclic nucleosides and nucleotides as therapeutic agents
09/14/2006CA2600675A1 Use of a combination of myxoma virus and rapamycin for therapeutic treatment
09/14/2006CA2600640A1 39-desmethoxy derivatives of rapamycin
09/14/2006CA2600638A1 Composition comprising emodepside and praziquantel or epsiprantel
09/14/2006CA2600637A1 Tetrahydro- and dihydroquinazolinones
09/14/2006CA2600636A1 New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
09/14/2006CA2600630A1 Substituted tetrahydropyrroloquinoline derivatives as kinase modulators, especially tyrosine kinase and raf kinase modulators
09/14/2006CA2600623A1 Azithromycin powder for oral suspension compositions
09/14/2006CA2600608A1 Composition comprising human igg2 antibody and chelating agent
09/14/2006CA2600558A1 Anti-proliferative combination therapy comprising satraplatin or jm118 and a taxane
09/14/2006CA2600475A1 Heteroarylsulfonyl stilbenes as 5-ht2a antagonists
09/14/2006CA2600429A1 Treatment with statin and omega-3 fatty acids and a combination product thereof
09/14/2006CA2600370A1 Bioactive fus1 peptides and nanoparticle-polypeptide complexes
09/14/2006CA2600358A1 Method for treatment of hepatic cancer
09/14/2006CA2600350A1 Use of opioid antagonists to attenuate endothelial cell proliferation and migration
09/14/2006CA2600339A1 Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and their use as estrogen receptor modulators
09/14/2006CA2600276A1 Polyphenol coxib combinations and methods
09/14/2006CA2600254A1 Benzoxazocines and their therapeutic use
09/14/2006CA2600178A1 Novel method for obtaining a fast-dissolving imidapril powder
09/14/2006CA2600169A1 Pyrazine -2-carboxamide derivatives as mglur5 antagonists
09/14/2006CA2600134A1 Methods and compositions for treating cancer
09/14/2006CA2600085A1 Microparticle and pharmaceutical preparation
09/14/2006CA2600067A1 Treatment of amyotrophic lateral sclerosis with pyrimethamine and analogues 6
09/14/2006CA2600064A1 Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues6
09/14/2006CA2600039A1 1,3-thiazole-5-carboxamides useful as cancer chemotherapeutic agents
09/14/2006CA2600035A1 Combination of a silicon containing component and a hormone
09/14/2006CA2600025A1 The use of thiophosphonoformic acid and nrtis to treat viral infections
09/14/2006CA2599974A1 Pyridine-2-carboxamide derivatives as mglur5 antagonists
09/14/2006CA2599968A1 Topical gels compositions
09/14/2006CA2599937A1 Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
09/14/2006CA2599879A1 Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
09/14/2006CA2599872A1 Novel salt of quinuclidine derivative
09/14/2006CA2599783A1 Use of an antagonist of epac for treating human cardiac hypertrophy
09/14/2006CA2599778A1 Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases
09/14/2006CA2599758A1 Pharmaceutical compositions comprising sirolimus and/or an analogue thereof
09/14/2006CA2599721A1 Pharmaceutical compositions for the treatment and/or prevention of depression
09/14/2006CA2599699A1 Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
09/14/2006CA2599577A1 Nucleic acids and proteins and methods for making and using them
09/14/2006CA2599547A1 Medical uses of 39-desmethoxyrapamycin and analogues thereof
09/14/2006CA2599511A1 2-(4-oxo-4h-quinazolin-3-yl) acetamides and their use as vasopressin v3 antagonists
09/14/2006CA2599376A1 Roflumilast for the treatment of diabetes mellitus
09/14/2006CA2599368A1 Amido-substituted 6-phenylphenanthridines
09/14/2006CA2599290A1 Ketoprofen sis adhesive for skin adhesive plaster
09/14/2006CA2599252A1 Carnitine-containing peritoneal dialysis solution having improved biocompatibility
09/14/2006CA2599251A1 Microemulsions of cannabinoid receptor binding compounds
09/14/2006CA2599250A1 Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds
09/14/2006CA2599186A1 Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists
09/14/2006CA2599125A1 Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
09/14/2006CA2598899A1 Novel hsp90 inhibitor
09/14/2006CA2598861A1 Organic compounds
09/14/2006CA2598613A1 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
09/14/2006CA2598530A1 Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
09/14/2006CA2598527A1 Ophthalmic uses of s1p receptor modulators